LaNua Medical, a brand new medical technology startup and has closed seed funding of €6 million. The funding will advance the commercialization of the company‘s novel Ecore device. It is intended to enhance the safety, efficacy, and efficiency of embolization procedures applied to tackle DAVFs, hemorrhage, and a myriad of tumors.
LaNua Medical: An Innovative Piece of Equipment
LaNua Medical is a startup company that was founded in April 2024 by a strong team of experienced specialists led by Cormac Farrelly, Tom Fitzmaurice, Eoin O’Cearbhaill, and Sajjad Amiri and based in Dublin, Ireland.
The Ecore device enables the doctor to control the blood flow to a particular vein or artery but at the same time allows other medical instruments, such as catheters and guidewires. This makes it easy to reduce radiation doses for both the patient and the practitioners, as well as eliminate any chances of errors during the procedures.
Transforming Patient Care
The Ecore device was designed to enhance current forms of embolization, which include liquid and microparticle embolization, as well as LIRT. LaNua’s technology will lead to increased safety and effectiveness of operations, especially in oncology, benign tumors, and hemostasis.
The company’s launch focus areas include liver cancer treatments. It also embolization with surgery has been shown to boost survival rates substantially.
Investor Support and Growth Plans
The seed round was co-led by Elkstone and Atlantic Bridge and also had the participation of Enterprise Ireland and Furthr VC. The amount of money raised will help to expand the hiring at LaNua and create new products for the market of embolization, which is expected to reach $3.88 billion by 2031. The company is expected to enter the U.S. market by 2027 with its products.
